Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

Citius Pharmaceuticals Inc. has provided an update on its advanced development programs in the biopharmaceutical sector. The company highlighted the launch of LYMPHIR (denileukin diftitox-cxdl) in December 2025 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is the first marketed product by Citius Oncology, Inc. (NASDAQ: CTOR), which became a stand-alone public company in August 2024 and remains a majority-owned subsidiary of Citius Pharmaceuticals. Other programs featured include Mino-Lok®, a treatment designed to salvage infected catheters causing central line-associated bloodstream infections (CLABSI), which has completed a Phase 3 trial with positive topline data, and Halo-Lido, a prescription therapy in development for hemorrhoids, which has completed a Phase 2b trial. The presentation notes that Citius Oncology has established a shared management services agreement with Citius Pharmaceuticals to support operational efficiency. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here